[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Mirvetuximab%20soravtansine\" }]"}]},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first ADC for ovarian cancer, for tumours with high folate receptor alpha.\"","after":"\"Mirvetuximab soravtansine (Elahere) is the first ADC for ovarian cancer, for tumours with high folate receptor alpha.\""}]}]